Display options
Cite
Hasbek Z, Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?. Mol Imaging Radionucl Ther. 2016;25(2):79-84doi: 10.4274/mirt.88598.
Hasbek, Z., & Turgut, B. (2016). Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?. Molecular imaging and radionuclide therapy, 25(2), 79-84. https://doi.org/10.4274/mirt.88598
Hasbek, Zekiye, and Turgut, Bülent. "Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?." Molecular imaging and radionuclide therapy vol. 25,2 (2016): 79-84. doi: https://doi.org/10.4274/mirt.88598
Hasbek Z, Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?. Mol Imaging Radionucl Ther. 2016 Jun 05;25(2):79-84. doi: 10.4274/mirt.88598. PMID: 27277324; PMCID: PMC5096624.
Copy Download .nbib Format: NLM
Share it on

Mol Imaging Radionucl Ther. 2016 Jun 05;25(2):79-84. doi: 10.4274/mirt.88598.

Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?.

Molecular imaging and radionuclide therapy

Zekiye Hasbek, Bülent Turgut

Affiliations

  1. Cumhuriyet University Faculty of Medicine, Department of Nuclear Medicine, Sivas, Turkey, Phone: +90 346 258 02 53 E-mail: [email protected].

PMID: 27277324 PMCID: PMC5096624 DOI: 10.4274/mirt.88598

Abstract

OBJECTIVE: Remnant ablation with radioactive iodine (I-131) is a successful form of treatment that aims to destroy the remaining residual tissue and/or metastatic tissue after total thyroidectomy in differentiated thyroid cancer (DTC) patients. High level of thyroid stimulating hormone (TSH) (≥30 mIU/L) is recommended for success of ablation treatment. In this retrospective study, our aim was to investigate whether the TSH levels at the time of ablation effect the success of radioactive iodine remnant ablation.

METHODS: Patients who were diagnosed with DTC, treated with bilateral total/near total thyroidectomy and who were referred for I-131 remnant ablation were included in this study. Patients with undetectable TSH-stimulated serum thyroglobulin (Tg) level, normal physical examination, negative results on whole body scan with I-131, and no evidence of neck lymph node metastasis on ultrasound were defined as disease-free. The correlation between TSH level at the time of ablation and ablation success was assessed.

RESULTS: Two hundred sixty one consecutive patients were included in the present study. Mean TSH level was 19.47±6 mIU/L in the 34 patients with TSH <30 mIU/L, while mean TSH level was 73.65±27 mIU/L in the 227 patients with TSH ≥30 mIU/L during I-131 remnant ablation. Ablation was unsuccessful in only one patient with TSH <30 mIU/L who had lung metastasis. Ablation was unsuccessful in 5.1% of patients with TSH ≥30 mIU/L. The effect of TSH level was not significant on ablation success (p=0.472).

CONCLUSION: In conclusion, we think that a high TSH serum level alone is not a factor for the success of ablation. Age, presence of metastasis, extent of residual thyroid mass should also be considered. Especially, in the presence of metastatic tissue, obtaining adequate increase in TSH level is not always possible. The success of ablation at lower levels of TSH elevations may be sufficient for patients, and long-term hypothyroidism may not be required.

Conflict of interest statement

No conflict of interest was declared by the authors.

References

  1. J Clin Endocrinol Metab. 1980 Apr;50(4):734-9 - PubMed
  2. J Clin Endocrinol Metab. 2002 Apr;87(4):1499-501 - PubMed
  3. Mol Imaging Radionucl Ther. 2014 Jun;23(2):54-9 - PubMed
  4. Ann Endocrinol (Paris). 2014 Jul;75(3):141-7 - PubMed
  5. Eur J Nucl Med Mol Imaging. 2015 Oct 23;:null - PubMed
  6. Asian Pac J Cancer Prev. 2014;15(15):6443-7 - PubMed
  7. Contemp Oncol (Pozn). 2012;16(3):273-5 - PubMed
  8. Arch Med Res. 2002 Sep-Oct;33(5):478-81 - PubMed
  9. Clin Chem. 2006 Jan;52(1):104-11 - PubMed
  10. J Clin Endocrinol Metab. 2004 Jul;89(7):3285-9 - PubMed
  11. Thyroid. 2016 Jan;26(1):1-133 - PubMed
  12. Thyroid. 2013 Feb;23(2):185-93 - PubMed
  13. Endocrinol Nutr. 2012 Apr;59(4):227-31 - PubMed
  14. Biomed Pharmacother. 2007 Sep;61(8):468-71 - PubMed
  15. J Thyroid Res. 2014;2014:610273 - PubMed
  16. Coll Antropol. 2012 Nov;36 Suppl 2:67-71 - PubMed
  17. Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1767-80 - PubMed

Publication Types